SNBL USA

Headquartered in Everett, Wash., and recognized as a leader in conducting GLP-compliant nonclinical toxicology studies, SNBL USA offers a wide-range of programs, from safety assessment and regulatory toxicology, to customized study designs. SNBL USA’s Acute Radiation Syndrome (ARS) program includes countermeasure evaluation resources, from exploratory animal efficacy studies to performing nonclinical GLP pivotal studies under the FDA’s Animal Rule in rodent, minipig and nonhuman primate animal models. This program allows SNBL USA to support drug development efforts for mitigating and treating radiation injury, as well as other important applications for this uniquely suited laboratory. SNBL USA, Ltd . is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL).